Naz Rahman
Stock Analyst at Maxim Group
(0.28)
# 4,024
Out of 4,814 analysts
38
Total ratings
15.62%
Success rate
-44.84%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.34 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $8.84 | +92.31% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $9 → $5 | $0.75 | +566.67% | 2 | Mar 20, 2025 | |
| SCPH scPharmaceuticals | Maintains: Buy | $20 → $12 | $2.57 | +366.93% | 3 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $23.83 | +193.75% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.02 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $4.23 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $0.72 | +1,012.66% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $2.04 | - | 2 | Oct 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.61 | +394.40% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $5.49 | +2,450.09% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $489.10 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.05 | +8,595.65% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.27 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.01 | +395.00% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.90 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.60 | +130.77% | 1 | Feb 25, 2022 |
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.34
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $8.84
Upside: +92.31%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $9 → $5
Current: $0.75
Upside: +566.67%
scPharmaceuticals
Mar 20, 2025
Maintains: Buy
Price Target: $20 → $12
Current: $2.57
Upside: +366.93%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $23.83
Upside: +193.75%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.02
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.23
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $0.72
Upside: +1,012.66%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.04
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.61
Upside: +394.40%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $5.49
Upside: +2,450.09%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $489.10
Upside: -
Dec 8, 2023
Initiates: Buy
Price Target: $4
Current: $0.05
Upside: +8,595.65%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.27
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $1.01
Upside: +395.00%
May 9, 2022
Downgrades: Hold
Price Target: n/a
Current: $0.90
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.60
Upside: +130.77%